AZD-9164 bromide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530403

CAS#: 1034916-72-7 (Br)

Description: AZD-9164 is a muscarinic M3 receptor antagonist potentially for the treatment of chronic obstructive pulmonary. AZD9164 may improve upon the therapeutic index of tiotropium, increasing the magnitude and duration of lung function improvements without increasing systemically-mediated adverse events.


Chemical Structure

img
AZD-9164 bromide
CAS# 1034916-72-7 (Br)

Theoretical Analysis

MedKoo Cat#: 530403
Name: AZD-9164 bromide
CAS#: 1034916-72-7 (Br)
Chemical Formula: C29H38BrFN2O2
Exact Mass: 0.00
Molecular Weight: 545.537
Elemental Analysis: C, 63.85; H, 7.02; Br, 14.65; F, 3.48; N, 5.14; O, 5.87

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1034978-04-5 (free base)   1034916-72-7 (Br)  

Synonym: AZD-9164; AZD 9164; AZD9164; AZD-9164 bromide.

IUPAC/Chemical Name: (R)-1-(4-fluorophenethyl)-3-(((S)-2-phenyl-2-(piperidin-1-yl)propanoyl)oxy)quinuclidin-1-ium bromide

InChi Key: QMMVAOGTOFQHAQ-BBCWMUSQSA-M

InChi Code: InChI=1S/C29H38FN2O2.BrH/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23;/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3;1H/q+1;/p-1/t24?,27-,29-,32?;/m0./s1

SMILES Code: C[C@](N1CCCCC1)(C2=CC=CC=C2)C(O[C@H]3C[N+]4(CCC5=CC=C(F)C=C5)CCC3CC4)=O.[Br-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS No. 1034978-04-5 (AZD-9164 Free) 1034916-72-7 (AZD-9164)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 545.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bergenholm L, Collins T, Evans ND, Chappell MJ, Parkinson J. PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data. J Pharmacol Toxicol Methods. 2016 May-Jun;79:34-44. doi: 10.1016/j.vascn.2016.01.002. PubMed PMID: 26780675.

2: Jorup C, Bengtsson T, Strandgården K, Sjöbring U. Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies. BMC Pulm Med. 2014 Mar 27;14:52. doi: 10.1186/1471-2466-14-52. PubMed PMID: 24669829; PubMed Central PMCID: PMC3976047.

3: Bjermer L, Bengtsson T, Jorup C, Lötvall J. Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respir Med. 2013 Jan;107(1):84-90. doi: 10.1016/j.rmed.2012.09.014. PubMed PMID: 23098686.

4: Silvester S, Zang F. Overcoming non-specific adsorption issues for AZD9164 in human urine samples: consideration of bioanalytical and metabolite identification procedures. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 15;893-894:134-43. doi: 10.1016/j.jchromb.2012.03.004. PubMed PMID: 22440890.

5: Mete A, Bowers K, Chevalier E, Donald DK, Edwards H, Escott KJ, Ford R, Grime K, Millichip I, Teobald B, Russell V. The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7440-6. doi: 10.1016/j.bmcl.2011.10.002. PubMed PMID: 22047691.